Dashboard
Manage Tickers

SRPTSarepta Therapeutics, Inc.

Nasdaq sarepta.com


$ 157.85 $ 0.04 (0.03 %)    

Friday, 28-Jun-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 158
$ 158.24
$ 0.00 x 0
$ 157.95 x 103
$ 156.15 - $ 159.71
$ 55.25 - $ 173.25
1,925,528
na
15.66B
$ 0.78
$ 926.79
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 10-31-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 03-01-2018 12-31-2017 10-K
27 11-01-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-25-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-26-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-sarepta-therapeutics-maintains-235-price-target
Needham Reiterates Buy on Sarepta Therapeu...
06/27/2024 10:06:55

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $235 price target.

looking-at-sarepta-therapeuticss-recent-unusual-options-activity
Looking At Sarepta Therapeutics's Recent U...
06/26/2024 15:16:27

citigroup-downgrades-sarepta-therapeutics-to-neutral-raises-price-target-to-176
Citigroup Downgrades Sarepta Therapeutics ...
06/26/2024 14:27:52

Citigroup analyst David Hoang downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Buy to Neutral and raises the price target ...

heres-how-much-you-would-have-made-owning-sarepta-therapeutics-stock-in-the-last-10-years
Here's How Much You Would Have Made Owning...
06/24/2024 20:00:30

morgan-stanley-maintains-overweight-on-sarepta-therapeutics-raises-price-target-to-200
Morgan Stanley Maintains Overweight on Sar...
06/24/2024 16:18:07

Morgan Stanley analyst Matthew Harrison maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price ...

evercore-isi-group-maintains-in-line-on-sarepta-therapeutics-raises-price-target-to-185
Evercore ISI Group Maintains In-Line on Sa...
06/24/2024 14:12:39

Evercore ISI Group analyst Gavin Clark-Gartner maintains Sarepta Therapeutics (NASDAQ:SRPT) with a In-Line and raises the pr...

micron-to-rally-around-23-here-are-10-top-analyst-forecasts-for-monday
Micron To Rally Around 23%? Here Are 10 To...
06/24/2024 12:25:05

bmo-capital-maintains-outperform-on-sarepta-therapeutics-raises-price-target-to-200
BMO Capital Maintains Outperform on Sarept...
06/24/2024 11:54:31

BMO Capital analyst Kostas Biliouris maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price tar...

leerink-partners-maintains-outperform-on-sarepta-therapeutics-raises-price-target-to-230
Leerink Partners Maintains Outperform on S...
06/24/2024 11:19:37

Leerink Partners analyst Mani Foroohar maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price t...

draftkings-and-dell-were-among-the-10-biggest-large-cap-stock-gainers-last-week-june-16-june-22-are-these-in-your-portfolio
DraftKings And Dell Were Among The 10 Bigg...
06/23/2024 15:43:40

Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKN...

growth-stocks-leave-value-stocks-in-the-dust-4-reasons-for-biggest-monthly-lead-in-over-a-year
Growth Stocks Leave Value Stocks In The Du...
06/21/2024 20:06:46

Technology sector dominates growth stocks, boosted by strong earnings and investor confidence. Value stocks struggle due to les...

nasdaq-moves-lower-factset-research-posts-upbeat-earnings
Nasdaq Moves Lower; FactSet Research Posts...
06/21/2024 18:58:10

why-kaival-brands-innovations-shares-are-trading-lower-by-47-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Kaival Brands Innovations Shares Are T...
06/21/2024 18:04:00

morgan-stanley-reiterates-overweight-on-sarepta-therapeutics-maintains-165-price-target
Morgan Stanley Reiterates Overweight on Sa...
06/21/2024 17:56:25

Morgan Stanley analyst Matthew Harrison reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and maintains $165 p...

sareptas-expanded-approval-unlikely-to-influence-novo-holdings-acquisition-of-catalent-but-provides-investor-protection-amid-uncertainty
Sarepta's Expanded Approval Unlikely To In...
06/21/2024 17:52:17

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/rew...

stocks-stall-as-chip-sector-struggles-to-rebound-dollar-eyes-7-week-peak-gold-bitcoin-retreat-whats-driving-markets-friday
Stocks Stall As Chip Sector Struggles To R...
06/21/2024 17:34:44

Wall Street is experiencing a subdued and low volatility trading day Friday, despite the session coinciding with the “triple wi...

piper-sandler-maintains-overweight-on-sarepta-therapeutics-maintains-157-price-target
Piper Sandler Maintains Overweight on Sare...
06/21/2024 17:06:36

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and maintains $157 price tar...

sareptas-expanded-fda-approval-for-elevidys-potentially-shaping-future-fda-reviews-analyst-says
Sarepta's Expanded FDA Approval For Elevid...
06/21/2024 16:50:38

FDA approves Sarepta's Elevidys for Duchenne muscular dystrophy patients with confirmed DMD gene mutation, aged 4+. Expande...

gold-down-1-carmax-shares-gain-after-q1-earnings
Gold Down 1%; CarMax Shares Gain After Q1 ...
06/21/2024 16:26:31

cantor-fitzgerald-reiterates-neutral-on-sarepta-therapeutics-maintains-128-price-target
Cantor Fitzgerald Reiterates Neutral on Sa...
06/21/2024 15:15:28

Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and maintains $128 pri...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)